Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Vericel Corp | a14-15471_1ex99d1.htm |
| EX-99.2 - EX-99.2 - Vericel Corp | a14-15471_1ex99d2.htm |
| EX-23.1 - EX-23.1 - Vericel Corp | a14-15471_1ex23d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 2, 2014
Aastrom Biosciences, Inc.
(Exact name of registrant as specified in its charter)
|
Michigan |
|
000-22025 |
|
94-3096597 |
|
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
24 Frank Lloyd Wright Drive, Lobby K, Ann Arbor, Michigan |
|
48105 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (734) 418-4400
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.01. Completion of Acquisition or Disposition of Assets.
This Form 8-K/A amends the Current Report on Form 8-K filed by Aastrom Biosciences, Inc. (the Company) on June 2, 2014 to provide additional financial information in connection with the acquisition by the Company of the cell therapy and regenerative medicine business (the CTRM Business) of Sanofi, a French société anonyme, which was completed on May 30, 2014 (the Transaction).
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
The Special Purpose Combined Statements of Net Assets Acquired for the CTRM Business as of March 31, 2014 (unaudited), December 31, 2013 and December 31, 2012, and the Special Purpose Combined Statements of Revenues and Direct Expenses for the three month periods ended March 31, 2014 (unaudited) and 2013 (unaudited) and for the years ended December 31, 2013 and 2012 are attached to this Form 8-K/A as Exhibit 99.1 and incorporated herein by reference.
(b) Pro Forma Financial Information.
The Pro Forma Condensed Combined Balance Sheet (unaudited) as of March 31, 2014 is attached to this Form 8-K/A as Exhibit 99.2 and incorporated herein by reference.
The Pro Forma Condensed Combined Statements of Operations (unaudited) for the year ended December 31, 2013 and for the quarter ended March 31, 2014 are attached to this Form 8-K/A as Exhibit 99.2 and incorporated herein by reference.
(d) Exhibits
|
Exhibit |
|
Description |
|
|
|
|
|
23.1 |
|
Consent of PricewaterhouseCoopers LLP, Independent Auditors. |
|
99.1 |
|
Special Purpose Combined Statements of Net Assets Acquired for the CTRM Business as of March 31, 2014 (unaudited), December 31, 2013 and December 31, 2012, and Special Purpose Combined Statements of Revenues and Direct Expenses for the three month periods ended March 31, 2014 (unaudited) and 2013(unaudited) and for the years ended December 31, 2013 and 2012. |
|
99.2 |
|
Pro Forma Condensed Combined Balance Sheet (unaudited) as of March 31, 2014 |
|
|
|
Pro Forma Condensed Combined Statements of Operations (unaudited) for the year ended December 31, 2013 and for the quarter ended March 31, 2014. |
Exhibit Index
|
Exhibit |
|
Description |
|
|
|
|
|
23.1 |
|
Consent of PricewaterhouseCoopers LLP, Independent Auditors. |
|
99.1 |
|
Special Purpose Combined Statements of Net Assets Acquired for the CTRM Business as of March 31, 2014 (unaudited), December 31, 2013 and December 31, 2012, and Special Purpose Combined Statements of Revenues and Direct Expenses for the three month periods ended March 31, 2014 (unaudited) and 2013(unaudited) and for the years ended December 31, 2013 and 2012. |
|
99.2 |
|
Pro Forma Condensed Combined Balance Sheet (unaudited) as of March 31, 2014 |
|
|
|
Pro Forma Condensed Combined Statements of Operations (unaudited) for the year ended December 31, 2013 and for the quarter ended March 31, 2014. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Aastrom Biosciences, Inc. | |
|
|
| |
|
Date: June 16, 2014 |
By: |
/s/ Dominick C. Colangelo |
|
|
|
Name: Dominick C. Colangelo |
|
|
|
Title: Chief Executive Officer and President |